COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA

被引：0
|
作者：
Guan, X. [1 ]
Li, H. [1 ]
Chen, Q. [2 ]
Hao, C. [3 ]
Li, J. [4 ]
Wang, Y. [5 ]
Zhang, J. [4 ]
Xu, H. [1 ]
Liu, C. [6 ]
Chu, Y. [7 ]
Ma, A. [1 ]
机构：
[1] China Pharmaceut Univ, Nanjing, Jiangsu, Peoples R China
[2] Guangdong Tradit Chinese Med Hosp, Guangzhou, Guangdong, Peoples R China
[3] Tianjin Med Univ Canc Hosp, Tianjin, Peoples R China
[4] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[5] Shandong Canc Hosp, Jinan, Shandong, Peoples R China
[6] Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China
[7] Shanghai Roche Pharmaceut Ltd, Beijing 11, Peoples R China
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CC4
引用
收藏
页码：S405 / S406
页数：2
相关论文
共 50 条
  • [31] Adjuvant chemotherapy for HER2-positive early breast cancer patients without perioperative radiotherapy in trastuzumab era
    Nozawa, Kazuki
    Sugiyama, Keiji
    Shiraishi, Kazuhiro
    Funahashi, Yoriko
    Kogure, Yoshihito
    Kawasaki, Tomonori
    Kato, Aya
    Kitagawa, Chiyoe
    Hayashi, Takako
    Morita, Takako
    Ichihara, Shu
    Saka, Hideo
    Sato, Yasuyuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada
    Attard, C. L.
    Pepper, A. N.
    Brown, S. T.
    Thompson, M. F.
    Thuresson, P. -O.
    Yunger, S.
    Dent, S.
    Paterson, A. H.
    Wells, G. A.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (03) : 173 - 188
  • [33] Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study
    Shao, Zhimin
    Tseng, Ling-Ming
    Huang, Chiun-Sheng
    Pang, Da
    Yang, Youngsen
    Li, Wei
    Liao, Ning
    Geng, Cuizhi
    Zhang, Qingyuan
    Xu, Binghe
    Liu, Donggeng
    Kwong, Ava
    Yu, Mandy
    Sun, Guofang
    Mobus, Volker
    Dent, Susan
    Arahmani, Amal
    Borthwick, Gillian
    Henot, Frederic
    von Minckwitz, Gunter
    Jiang, Zefei
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 345 - 353
  • [34] Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis
    Khoirunnisa, Sudewi Mukaromah
    Suryanegara, Fithria Dyah Ayu
    Setiawan, Didik
    Postma, Maarten Jacobus
    de Jong, Lisa Aniek
    [J]. PLOS ONE, 2024, 19 (05):
  • [35] Trastuzumab after adjuvant chemotherapy: survival benefit in HER2-positive breast cancer
    [J]. Nature Clinical Practice Oncology, 2007, 4 (4): : 208 - 209
  • [36] Use of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
    Elkerm, Y.
    Ali, I. M.
    Elsaid, A. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Trastuzumab (Herceptin®) for treatment of HER2-positive metastatic breast cancer:: a cost-effectiveness analysis.
    Hornberger, J
    Foutel, V
    Kerrigan, M
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S136 - S136
  • [38] Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report
    Yamashita, Yuji
    Tanaka, Yuko
    Kono, Seishi
    Nishimura, Meiko
    Mukohara, Toru
    Morinaga, Yukiko
    Hara, Shigeo
    Takao, Shintaro
    [J]. BREAST CARE, 2017, 12 (01) : 45 - 47
  • [39] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    [J]. WOMENS HEALTH, 2009, 5 (02) : 135 - 147
  • [40] Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore
    Cheng, Li-Jen
    Loke, Lydia
    Lim, Elaine Hsuen
    Pearce, Fiona
    Aziz, Mohamed Ismail Abdul
    Ng, Kwong
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 449 - 456
12345